GLP-1 Tirzepatide ReviewIndependent · S.J Partners LLC
Prices 9 verified of 64 Rubric v1.0-draft Prices verified 0 of 64 Evidence records 54 verified Corrections open log

Guide

GLP-1 Prior Authorization: What Plans Ask For and How to Prepare

Prior authorization is a documentation exercise, not a clinical argument. Plans publish criteria; approval turns on whether your record contains the specific elements tho

Direct answer

Prior authorization is a documentation exercise, not a clinical argument. Plans publish criteria; approval turns on whether your record contains the specific elements those criteria name, in the format the reviewer expects. Getting the written criteria before submission is the single highest-yield step.

Answer last reviewed: 2026-07-26

What prior authorization actually is

A requirement that your plan approve a drug before it will pay. The plan publishes criteria, your prescriber submits documentation, and a reviewer decides whether the documentation matches.

That framing matters because it tells you where to put effort. Most denials are not the plan disagreeing that you need the drug. They are the submission failing to contain something the criteria require, in a form the reviewer could find.

Get the criteria first

Ask your plan for the prior-authorization criteria for the specific drug, in writing. Many publish them; all will provide them on request. This single step changes the exercise from guessing to matching.

Read them literally. If the criteria name a BMI threshold with a comorbidity, the submission needs both documented, with dates. If they require a documented trial of lifestyle intervention over a stated period, a note saying "patient has tried diet and exercise" will not satisfy it.

What criteria commonly require

These vary by plan and this is not a checklist to submit — it is what to expect so you can ask your prescriber whether your record covers it.

  • BMI thresholds, often with an alternative lower threshold where a weight-related comorbidity is present.
  • Documented comorbidity, coded, not described in narrative.
  • Prior lifestyle intervention, frequently with a duration requirement.
  • Step therapy — a documented trial of a preferred alternative, with the outcome recorded.
  • Baseline measurements with dates in the record.
  • Exclusion screening, notably personal or family history of medullary thyroid carcinoma or MEN 2, which are contraindications on the label.

Where submissions fail

Missing dates. A criterion requiring six months of documented intervention needs entries showing that period, not a summary written today.

Narrative instead of codes. Reviewers work from structured data. A comorbidity described in free text may not register.

The wrong indication. If your plan covers a molecule for diabetes and not for weight management, submitting under the weight-management indication produces a denial that is procedurally correct.

Step therapy unaddressed. If a preferred alternative exists, the submission needs to say what happened when it was tried, or why it is contraindicated.

What you can usefully do

Bring your prescriber the written criteria. Ask directly whether your record contains each element and, where it does not, what would be needed. Ask who at the practice handles prior authorizations — in many, it is a specific administrator rather than the clinician, and reaching them saves weeks.

Keep your own copy of what was submitted and when. If it is denied, you appeal against a specific document, and you will want to know what the reviewer actually saw.

Timelines

Standard determinations typically run days to a couple of weeks; expedited review exists where a delay would jeopardise health, and your prescriber requests it. If a decision is overdue, call and cite the date of submission. Plans have deadlines and they are enforceable.

If it is denied

A first-level denial is routinely overturned on appeal, particularly where the denial was documentary rather than clinical. See the appeal guide, and request the denial reason in writing before doing anything else.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Questions readers actually ask

How long does GLP-1 prior authorization take?

Standard determinations typically take days to a couple of weeks. Expedited review exists where delay would jeopardise health and is requested by the prescriber.

Why was my prior authorization denied?

Most denials are documentary rather than clinical — a criterion the submission did not address, missing dates, an unaddressed step-therapy requirement, or the wrong indication.

Can I see the criteria my plan uses?

Yes. Ask your plan for the prior-authorization criteria for the specific drug in writing. Many publish them and all will provide them on request.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “GLP-1 Prior Authorization: What Plans Ask For and How to Prepare.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/insurance/prior-authorization/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Report an error
Comparing 0 of 4